These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

198 related articles for article (PubMed ID: 39274973)

  • 1. Cytotoxic Activity of Novel GnRH Analogs Conjugated with Mitoxantrone in Ovarian Cancer Cells.
    Markatos C; Biniari G; Chepurny OG; Karageorgos V; Tsakalakis N; Komontachakis G; Vlata Z; Venihaki M; Holz GG; Tselios T; Liapakis G
    Molecules; 2024 Aug; 29(17):. PubMed ID: 39274973
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Rational Design, Synthesis and Binding Affinity Studies of Anthraquinone Derivatives Conjugated to Gonadotropin-Releasing Hormone (GnRH) Analogues towards Selective Immunosuppression of Hormone-Dependent Cancer.
    Biniari G; Markatos C; Nteli A; Tzoupis H; Simal C; Vlamis-Gardikas A; Karageorgos V; Pirmettis I; Petrou P; Venihaki M; Liapakis G; Tselios T
    Int J Mol Sci; 2023 Oct; 24(20):. PubMed ID: 37894912
    [TBL] [Abstract][Full Text] [Related]  

  • 3. In vitro targeting of a cytotoxic analog of luteinizing hormone-releasing hormone AN-207 to ES-2 human ovarian cancer cells as demonstrated by microsatellite analyses.
    Arencibia JM; Schally AV; Halmos G; Nagy A; Kiaris H
    Anticancer Drugs; 2001 Jan; 12(1):71-8. PubMed ID: 11272290
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Increase of doxorubicin-induced apoptosis after knock-down of gonadotropin-releasing hormone receptor expression in human endometrial, ovarian and breast cancer cells.
    Fister S; Schlotawa L; Günthert AR; Emons G; Gründker C
    Gynecol Endocrinol; 2008 Jan; 24(1):24-9. PubMed ID: 17943530
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Oxime bond-linked daunorubicin-GnRH-III bioconjugates exert antitumor activity in castration-resistant prostate cancer cells via the type I GnRH receptor.
    Montagnani Marelli M; Manea M; Moretti RM; Marzagalli M; Limonta P
    Int J Oncol; 2015 Jan; 46(1):243-53. PubMed ID: 25351635
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Development of programmable gemcitabine-GnRH pro-drugs bearing linker controllable "click" oxime bond tethers and preclinical evaluation against prostate cancer.
    Vrettos EI; Karampelas T; Sayyad N; Kougioumtzi A; Syed N; Crook T; Murphy C; Tamvakopoulos C; Tzakos AG
    Eur J Med Chem; 2021 Feb; 211():113018. PubMed ID: 33223264
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Gonadotropin-releasing hormone type II antagonists induce apoptotic cell death in human endometrial and ovarian cancer cells in vitro and in vivo.
    Fister S; Günthert AR; Emons G; Gründker C
    Cancer Res; 2007 Feb; 67(4):1750-6. PubMed ID: 17308117
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Role of gonadotropin-releasing hormone (GnRH) in ovarian cancer.
    Gründker C; Emons G
    Reprod Biol Endocrinol; 2003 Oct; 1():65. PubMed ID: 14594454
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Mechanism of gonadotropin-releasing hormone (GnRH)-I and -II-induced cell growth inhibition in ovarian cancer cells: role of the GnRH-I receptor and protein kinase C pathway.
    Kim KY; Choi KC; Auersperg N; Leung PC
    Endocr Relat Cancer; 2006 Mar; 13(1):211-20. PubMed ID: 16601289
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Luteinizing hormone-releasing hormone receptor-mediated delivery of mitoxantrone using LHRH analogs modified with PEGylated liposomes.
    He Y; Zhang L; Song C
    Int J Nanomedicine; 2010 Sep; 5():697-705. PubMed ID: 20957221
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Gonadotropin-releasing hormone (GnRH) receptors in tumors: a new rationale for the therapeutical application of GnRH analogs in cancer patients?
    Montagnani Marelli M; Moretti RM; Januszkiewicz-Caulier J; Motta M; Limonta P
    Curr Cancer Drug Targets; 2006 May; 6(3):257-69. PubMed ID: 16712461
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Luteinizing hormone-releasing hormone receptor-targeted chemotherapy using AN-152.
    Emons G; Sindermann H; Engel J; Schally AV; Gründker C
    Neuroendocrinology; 2009; 90(1):15-8. PubMed ID: 19521066
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Expression of gonadotropin-releasing hormone II (GnRH-II) receptor in human endometrial and ovarian cancer cells and effects of GnRH-II on tumor cell proliferation.
    Gründker C; Günthert AR; Millar RP; Emons G
    J Clin Endocrinol Metab; 2002 Mar; 87(3):1427-30. PubMed ID: 11889221
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Effect of gonadotropin-releasing hormone agonist on ES-2 ovarian cancer cells.
    Tsui KH; Lee WL; Seow KM; Yang LW; Wang SY; Wang PH; Chang CL; Yen MS; Cheng JT; Chen CP
    Taiwan J Obstet Gynecol; 2014 Mar; 53(1):35-42. PubMed ID: 24767644
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Growth inhibition of tumor cells in vitro by using monoclonal antibodies against gonadotropin-releasing hormone receptor.
    Lee G; Ge B
    Cancer Immunol Immunother; 2010 Jul; 59(7):1011-9. PubMed ID: 20182875
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Peptidomimetic GnRH antagonist AEZS-115 inhibits the growth of ovarian and endometrial cancer cells.
    Engel JB; Hahne JC; Häusler SF; Meyer S; Segerer SE; Diessner J; Dietl J; Honig A
    Anticancer Res; 2012 May; 32(5):2063-8. PubMed ID: 22593489
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Design of multifunctional magnetic iron oxide nanoparticles/mitoxantrone-loaded liposomes for both magnetic resonance imaging and targeted cancer therapy.
    He Y; Zhang L; Zhu D; Song C
    Int J Nanomedicine; 2014; 9():4055-66. PubMed ID: 25187709
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Comparative in vitro biological evaluation of daunorubicin containing GnRH-I and GnRH-II conjugates developed for tumor targeting.
    Szabó I; Bősze S; Orbán E; Sipos É; Halmos G; Kovács M; Mező G
    J Pept Sci; 2015 May; 21(5):426-35. PubMed ID: 25908176
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Differential role of gonadotropin-releasing hormone on human ovarian epithelial cancer cell invasion.
    Chen CL; Cheung LW; Lau MT; Choi JH; Auersperg N; Wang HS; Wong AS; Leung PC
    Endocrine; 2007 Jun; 31(3):311-20. PubMed ID: 17906381
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Targeting of cytotoxic luteinizing hormone-releasing hormone analogs to breast, ovarian, endometrial, and prostate cancers.
    Nagy A; Schally AV
    Biol Reprod; 2005 Nov; 73(5):851-9. PubMed ID: 16033997
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 10.